Eiger BioPharmaceuticals To Focus Development On Advancing Avexitide In Hyperinsulinemic Hypoglycemia Indications; Will Explore Strategic Partnering Options In Late-Stage Virology Programs And Reduce Workforce By 25%
Portfolio Pulse from Benzinga Newsdesk
Eiger BioPharmaceuticals announced its decision to focus on advancing Avexitide in hyperinsulinemic hypoglycemia indications. The company will also explore strategic partnering options in late-stage virology programs and reduce its workforce by 25%.
June 29, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Eiger BioPharmaceuticals' decision to focus on Avexitide and explore strategic partnerships could potentially attract investors. However, the workforce reduction might negatively impact the company's operations in the short term.
The company's decision to focus on Avexitide could potentially lead to a breakthrough in hyperinsulinemic hypoglycemia treatment, which could attract investors. Exploring strategic partnerships could also open up new opportunities for the company. However, the decision to reduce the workforce by 25% could potentially impact the company's operations and productivity in the short term, which might be a concern for investors.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100